Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Cancer|Breast Cancer
Interventions: DRUG: Romidepsin|DRUG: Cisplatin|DRUG: Nivolumab
Sponsor: Priyanka Sharma
Collaborators: Celgene Corporation|Bristol-Myers Squibb